Key result
Pemafibrate reduced triglyceride levels at all doses in statin-treated patients, with a maximum placebo-corrected reduction of 54.4% at twice daily.
Why the study?
High triglycerides are an independent cardiovascular risk factor, but currently available fibrates have relatively low selectivity for PPARα.
Does pemafibrate reduce TG and non-HDL-C levels in statin-treated European adults with hypertriglyceridemia?
RCT (n=408)
double-blind
randomly assigned
Yes
Does pemafibrate reduce TG and non-HDL-C levels in statin-treated European adults with hypertriglyceridemia?
Pemafibrate effectively reduces triglyceride levels in statin-treated patients with hypertriglyceridemia, though it does not significantly lower non-HDL-C.
Answers are grounded in this paper and cite their sources.
May inform management of persistent hypertriglyceridemia on statins; extends RCT evidence for selective PPARα agonism.
OBJECTIVE: High plasma triglyceride (TG) is an independent risk factor for cardiovascular disease. Fibrates lower TG levels through peroxisome proliferator-activated receptor α (PPARα) agonism. Currently available fibrates, however, have relatively low selectivity for PPARα. The aim of this trial was to assess the safety, tolerability, and efficacy of K-877 (pemafibrate), a selective PPARα modulator, in statin-treated European patients with hypertriglyceridemia. RESEARCH DESIGN AND METHODS: A total of 408 statin-treated adults were recruited from 68 European sites for this phase 2, randomized, double-blind, placebo-controlled trial. They had fasting TG between 175 and 500 mg/dL and HDL-cholesterol (HDL-C) ≤50 mg/dL for men and ≤55 mg/dL for women. Participants were randomly assigned to receive placebo or one of six pemafibrate regimens: 0.05 mg twice a day, 0.1 mg twice a day, 0.2 mg twice a day, 0.1 mg once daily, 0.2 mg once daily, or 0.4 mg once daily. The primary end points were TG and non-HDL-C level lowering at week 12. RESULTS: Pemafibrate reduced TG at all doses (adjusted P value <0.001), with the greatest placebo-corrected reduction from baseline to week 12 observed in the 0.2-mg twice a day treatment group (54.4%). Reductions in non-HDL-C did not reach statistical significance. Reductions in TG were associated with improvements in other markers for TG-rich lipoprotein metabolism, including reductions in apoB48, apoCIII, and remnant cholesterol and an increase in HDL-C levels. Pemafibrate increased LDL-cholesterol levels, whereas apoB100 was unchanged. Pemafibrate was safe and well-tolerated, with only minor increases in serum creatinine and homocysteine concentrations. CONCLUSIONS: Pemafibrate is effective, safe, and well-tolerated for the reduction of TG in European populations with hypertriglyceridemia despite statin treatment.
No takes yet. Share an insight, caveat, or question.
Ginsberg et al. (2022) conducted an RCT in hypertriglyceridemia (n=408). K-877 (pemafibrate) vs. placebo was evaluated on TG and non-HDL-C level lowering at week 12 (p=<0.001). Pemafibrate reduced triglyceride levels at all doses in statin-treated patients, with a maximum placebo-corrected reduction of 54.4% at twice daily.
Synapse has enriched 10 related papers. Consider them for comparative context: